文献速递前列腺癌

转移性前列腺癌基因组改变的临床意义

Clinical implications of genomic alterations in metastatic prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-01-15

本文综述了转移性前列腺癌中基因组改变对预后和治疗选择的潜在价值。通过组织活检和循环肿瘤DNA检测,可识别与侵袭性疾病相关的特定基因组改变,并指导AR信号抑制剂、PARP抑制剂、免疫检查点抑制剂及PI3K通路抑制剂等靶向治疗的应用。

要点

  • 基因组亚型有助于改善转移性前列腺癌的预后判断和治疗选择。
  • AR通路改变与AR信号抑制剂及其他标准治疗的疗效相关。
  • DNA损伤修复缺陷可预测PARP抑制剂或免疫检查点抑制剂的疗效。

核心结论

  • 基因组亚型分析有潜力改善转移性前列腺癌的预后判断并指导治疗选择。

研究设计与样本

  • 本文为综述,总结了组织活检和循环肿瘤DNA检测揭示的基因组改变与临床结局的关联数据。

主要发现

  • AR通路改变与患者对AR信号抑制剂及其他标准治疗的反应相关。
  • 不同类型的DNA损伤修复缺陷与靶向治疗(如PARP抑制剂或免疫检查点抑制剂)的临床结局相关。
  • PI3K信号通路抑制剂处于晚期临床开发阶段,可能在特定分子亚型的转移性前列腺癌中产生影响。

临床怎么用

  • 可利用基因组亚型分析改善转移性前列腺癌的预后判断和治疗选择。
  • 根据AR通路改变、DNA损伤修复缺陷等分子特征选择靶向治疗。
  • 关注基于血液的分析物在预后和预测生物标志物开发中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There has been a rapid expansion in treatment options for the management of metastatic prostate cancer, but individual patient outcomes can be variable due to inter-patient tumor heterogeneity. Fortunately, the disease can be stratified on the basis of common somatic features, providing potential for the development of clinically useful prognostic and predictive biomarkers. Tissue biopsy programs and studies leveraging circulating tumor DNA (ctDNA) have revealed specific genomic alterations that are associated with aggressive disease biology. In this review, we discuss the potential for genomic subtyping to improve prognostication and to help guide treatment selection. We summarize data on associations between AR pathway alterations and patient response to AR signaling inhibitors and other standards of care. We describe the links between detection of different types of DNA damage repair defects and clinical outcomes with targeted therapies such as poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors or immune checkpoint inhibitors. PI3K signaling pathway inhibitors are also in advanced clinical development and we report upon the potential for these and other novel targeted therapies to have impact in specific molecular subsets of metastatic prostate cancer. Finally, we discuss the growing use of blood-based analytes for prognostic and predictive biomarker development, and summarize ongoing prospective biomarker-driven clinical trials.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sumiyoshi T, Chi KN, Wyatt AW, et al. Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33452452. doi:10.1038/s41391-020-00308-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。